GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 1, 2011, Pages 72-79

  Zhou, Liqing ^a   Zhang, Xiaojiao ^b   Chen, Xuechao ^c   Liu, Li ^b   Lu, Chao ^b   Tang, Xiaohu ^b   Shi, Juan ^b   Li, Meng ^b   Zhou, Mo ^b   Zhang, Zhouwei ^b   Xiao, Lingchen ^b   Yang, Ming ^b  

^a Huaian No 2 Hospital   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Gastrointestinal cancer; Group specific component; Single nucleotide polymorphism; Susceptibility

Indexed keywords

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GROUP SPECIFIC COMPONENT GENE; HAPLOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

EID: 84863036879     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980; 9: 227-231.
2. Bostick RM, Potter JD, Sellers TA, McKenzie DR, Kushi LH and Folsom AR. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am J Epidemiol 1993; 137: 1302-1317.
3. Martínez ME, Marshall JR, Sampliner R, Wilkinson J and Alberts DS. Calcium, vitamin D, and risk of adenoma recurrence (United States). Cancer Causes Control 2002; 13: 213-220.
4. Martínez ME, Giovannucci EL, Colditz GA, Stampfer MJ, Hunter DJ, Speizer FE, Wing A and Willett WC. Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst 1996; 88: 1375-1382.
5. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ and Willett WC.Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98: 451-459.
6. Pritchard RS, Baron JA and Gerhardsson de Verdier M. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers Prev 1996; 5: 897-900.
7. Marcus PM, Newcomb PA. The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 1998; 27: 788-793.
8. Kampman E, Slattery ML, Caan B and Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes Control 2000; 11: 459-466.
9. Lipworth L, Rossi M, McLaughlin JK, Negri E, Talamini R, Levi F, Franceschi S and La Vecchia C. Dietary vitamin D and cancers of the oral cavity and esophagus. Ann Oncol 2009; 20: 1576-1581.
10. Ikezaki S, Nishikawa A, Furukawa F, Tanakamura Z, Kim HC, Mori H and Takahashi M. Chemopreventive effects of 24R,25- dihydroxyvitamin D3, a vitamin D3 derivative, on glandular stomach carcinogenesis induced in rats by N-methyl-N'-nitro-N-nitrosoguanidine and sodium chloride. Cancer Res 1996; 56: 2767-2770.
11. La Vecchia C, Ferraroni M, D'Avanzo B, Decarli A and Franceschi S. Selected micronutrient intake and the risk of gastric cancer. Cancer Epidemiol Biomarkers Prev 1994; 3: 393-398.
12. Jourdan JL, Akhter J, Bowrey P, Pourgholami M and Morris DL. Hepatic intra-arterial injection of lipiodol-1,25-dihydroxyvitamin D3 for hepatocellular carcinoma in rats. Anticancer Res 2000; 20: 2739-2744.
13. Pourgholami MH, Morris DL. 1,25- Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. J Steroid Biochem Mol Biol 2004; 89-90: 513-518.
14. Pourgholami MH, Akhter J, Lu Y and Morris DL. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett 2000; 151: 97-102.
15. Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of B-galactosidase of B cells and sialidase of T cells. J Immunol 1993; 151: 2794-2802.
16. Yamamoto N, Naraparaju VR. Role of vitamin D3-binding protein in activation of mouse macrophages. J Immunol 1996; 157: 1744-1749.
17. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N and Pirie-Shepherd S. Vitamin D binding proteinmacrophage activating factor (DBP- maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003; 5: 32-40.
18. Yamamoto N, Suyama H, Yamamoto N and Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 2008; 122: 461-467.
19. Sinotte M, Diorio C, Berube S, Pollak M and Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009; 89: 634-640.
20. Engelman CD, Fingerlin TE, Langefeld CD, Hicks PJ, Rich SS, Wagenknecht LE, Bowden DW and Norris JM. Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25- dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab 2008; 93: 3381-3388.
21. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P and Albanes D. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010; 19: 2739-2745.
22. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E and Spector TD. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-188.
23. McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, Thun MJ and Calle EE. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 2007; 9: R9.
24. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D and Chang-Claude J. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 2008; 17: 1339-1343.
25. Anderson LN, Cotterchio M, Cole DE and Knight JA. Vitamin D-Related Genetic Variants, Interactions with Vitamin D Exposure, and Breast Cancer Risk among Caucasian Women in Ontario. Cancer Epidemiol Biomarkers Prev 2011; 20: 1708-1717.
26. Kidd LC, Paltoo DN, Wang S, Chen W, Akereyeni F, Isaacs W, Ahaghotu C and Kittles R. Sequence variation within the 5' regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate 2005; 64: 272-282.
27. Poynter JN, Jacobs ET, Figueiredo JC, Lee WH, Conti DV, Campbell PT, Levine AJ, Limburg P, Le Marchand L, Cotterchio M, Newcomb PA, Potter JD, Jenkins MA, Hopper JL, Duggan DJ, Baron JA and Haile RW. Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2010; 19: 525-536.
28. Flohil SC, de Vries E, van Meurs JB, Fang Y, Stricker BH, Uitterlinden AG and Nijsten T. Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas. Exp Dermatol 2010; 19: 1103-1105.
29. Schaid DJ, Rowland CM, Tines DE, Jacobson RM and Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
30. Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 2007; 28: 1373-1382.
31. Braun A, Bichlmaier R and Cleve H. Molecular analysis of the gene for the human vitamin-Dbinding protein (group-specific component): allelic differences of the common genetic GC types. Hum Genet 1992; 89: 401-406.
32. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993; 92: 183-188.
33. Lauridsen AL, Vestergaard P and Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem 2001; 47: 753-756.
34. Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L and Nexo E. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005; 77: 15-22.